The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.
 
Todd Michael Bauer
Employment - Tennessee Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Exelixis; Foundation Medicine; Guardant Health; Ignyta (Inst); Loxo; Moderna Therapeutics (Inst); Pfizer; Pfizer (Inst)
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Lilly
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Peleton (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Principa Biopharma (Inst); Roche (Inst); Sanofi (Inst); Stemline Therapeutics (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Novartis; Pfizer; Pharmacyclics; Sysmex
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche
Consulting or Advisory Role - Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Novartis
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Lilly; Novartis
 
Richard Greil
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Merck; MSD; Novartis; Roche; Sandoz; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen; Merck; MSD; Novartis; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gilead Sciences (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Sandoz (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen-Cilag; MSD; Novartis; Roche
 
Maria-Elisabeth Goebeler
Consulting or Advisory Role - Bristol-Myers Squibb; GEMoaB; Novartis; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GEMoaB; Pfizer; Roche
 
Marie Luise Huetter-Kroenke
Stock and Other Ownership Interests - BioNTech (I); Moderna Therapeutics (I)
 
Ignacio Garrido-Laguna
Consulting or Advisory Role - Array BioPharma; Eisai
Research Funding - ARMO BioSciences (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Glenmark (Inst); Halozyme (Inst); Ignyta (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst)
 
Armando Santoro
Consulting or Advisory Role - ARQULE; Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; MSD; Pfizer; Sanofi; SERVIER
Speakers' Bureau - Abbvie; Amgen; ArQule; AstraZeneca; Bayer; BMS; Celgene; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Sandoz; Servier; Takeda
 
Antonella Perotti
No Relationships to Disclose
 
Anna Spreafico
Honoraria - Bristol-Myers Squibb; Janssen Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Oncorus
Research Funding - Alkermes; Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Northern Biologics; Novartis; Replimune; Roche; Surface Oncology; Symphogen
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Janssen Oncology; Merck; Roche
 
Thomas Yau
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology
Consulting or Advisory Role - Bristol-Myers Squibb
 
Markus Joerger
No Relationships to Disclose
 
Viviana Cremasco
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Mirek Dostalek
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Patents, Royalties, Other Intellectual Property - Novartis
 
Marc Pelletier
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Louise Barys
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Darlene Lu
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Vicky Katsanou
Employment - Novartis; Novartis (I)
Stock and Other Ownership Interests - Novartis; Novartis (I)
 
Claire Fabre
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Toshihiko Doi
Honoraria - Abbvie; Astellas Pharma; Bristol-Myers Squibb Japan; Oncolys BioPharma; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; Bayer; Boehringer Ingelheim; Daiichi Sankyo; MSD; Novartis; Otsuka; Rakuten Medical; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst)